The 36-month beta value for PHAT is at 0.01. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for PHAT is 39.42M, and currently, shorts hold a 27.70% of that float. The average trading volume for PHAT on May 14, 2025 was 1.64M shares.
PHAT) stock’s latest price update
The stock of Phathom Pharmaceuticals Inc (NASDAQ: PHAT) has decreased by -1.21 when compared to last closing price of 3.31.Despite this, the company has seen a gain of 36.25% in its stock price over the last five trading days. zacks.com reported 2025-05-08 that Phathom Pharmaceuticals (PHAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
PHAT’s Market Performance
PHAT’s stock has risen by 36.25% in the past week, with a monthly drop of -29.37% and a quarterly drop of -40.33%. The volatility ratio for the week is 22.56% while the volatility levels for the last 30 days are 13.67% for Phathom Pharmaceuticals Inc The simple moving average for the last 20 days is -6.34% for PHAT’s stock, with a simple moving average of -66.63% for the last 200 days.
Analysts’ Opinion of PHAT
Many brokerage firms have already submitted their reports for PHAT stocks, with Cantor Fitzgerald repeating the rating for PHAT by listing it as a “Overweight.” The predicted price for PHAT in the upcoming period, according to Cantor Fitzgerald is $23 based on the research report published on February 14, 2025 of the current year 2025.
Stifel, on the other hand, stated in their research note that they expect to see PHAT reach a price target of $24. The rating they have provided for PHAT stocks is “Buy” according to the report published on May 03rd, 2024.
Needham gave a rating of “Buy” to PHAT, setting the target price at $26 in the report published on January 05th of the previous year.
PHAT Trading at -28.91% from the 50-Day Moving Average
After a stumble in the market that brought PHAT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.41% of loss for the given period.
Volatility was left at 13.67%, however, over the last 30 days, the volatility rate increased by 22.56%, as shares sank -28.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.89% lower at present.
During the last 5 trading sessions, PHAT rose by +42.08%, which changed the moving average for the period of 200-days by -70.95% in comparison to the 20-day moving average, which settled at $3.50. In addition, Phathom Pharmaceuticals Inc saw -59.73% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PHAT starting from Topper James N, who purchase 35,602 shares at the price of $3.22 back on May 09 ’25. After this action, Topper James N now owns 35,602 shares of Phathom Pharmaceuticals Inc, valued at $114,616 using the latest closing price.
Topper James N, the Director of Phathom Pharmaceuticals Inc, purchase 12,601 shares at $3.04 during a trade that took place back on May 12 ’25, which means that Topper James N is holding 48,203 shares at $38,301 based on the most recent closing price.
Stock Fundamentals for PHAT
Current profitability levels for the company are sitting at:
- -3.5 for the present operating margin
- 0.86 for the gross margin
The net margin for Phathom Pharmaceuticals Inc stands at -3.07. The total capital return value is set at -1.3.
Based on Phathom Pharmaceuticals Inc (PHAT), the company’s capital structure generated -1.51 points at debt to capital in total, while cash flow to debt ratio is standing at -1.39. The debt to equity ratio resting at -0.6. The interest coverage ratio of the stock is -3.93.
Currently, EBITDA for the company is -261.52 million with net debt to EBITDA at 0.03. When we switch over and look at the enterprise to sales, we see a ratio of 2.65. The receivables turnover for the company is 2.25for trailing twelve months and the total asset turnover is 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.58.
Conclusion
In conclusion, Phathom Pharmaceuticals Inc (PHAT) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
